L-Carnitine inner salt
(Synonyms: 左旋肉碱; (R)-Carnitine; Levocarnitine) 目录号 : GN10558
A conditionally essential nutrient
Cas No.:541-15-1
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
L-carnitine (Levocarnitine) is constituent of striated muscle and liver. It is used therapeutically to stimulate gastric and pancreatic secretions and in the treatment of hyperlipoproteinemias.Target: OthersL-carnitine (Levocarnitine) is an endogenous molecule involved in fatty acid metabolism, biosynthesized within the human body using amino acids: L-lysine and L-methionine, as substrates. L-carnitine (Levocarnitine) can also be found in many foods, but red meats, such as beef and lamb, are the best choices for adding carnitine into the diet [1]. Administering L-carnitine (510 mg/day) to patients with the disease. L-carnitine (Levocarnitine) treatment significantly improved the total time for dozing off during the daytime, calculated from the sleep logs, compared with that of placebo-treated periods. L-carnitine (Levocarnitine) efficiently increased serum acylcarnitine levels, and reduced serum triglycerides concentration [2]. L-carnitine (Levocarnitine) and its derivatives show promise in the treatment of chronic conditions and diseases associated with mitochondrial dysfunction but further translational studies are needed to fully explore their potential [3].
References:
[1]. Marcovina, S.M., et al., Translating the basic knowledge of mitochondrial functions to metabolic therapy: role of L-carnitine. Transl Res, 2013. 161(2): p. 73-84.
[2]. Pekala, J., et al., L-carnitine--metabolic functions and meaning in humans life. Curr Drug Metab, 2011. 12(7): p. 667-78.
[3]. Miyagawa, T., et al., Effects of oral L-carnitine administration in narcolepsy patients: a randomized, double-blind, cross-over and placebo-controlled trial. PLoS One, 2013. 8(1): p. e53707.
| Cas No. | 541-15-1 | SDF | |
| 别名 | 左旋肉碱; (R)-Carnitine; Levocarnitine | ||
| 化学名 | (3R)-3-hydroxy-4-(trimethylazaniumyl)butanoate | ||
| Canonical SMILES | C[N+](C)(C)CC(CC(=O)[O-])O | ||
| 分子式 | C7H15NO3 | 分子量 | 161.2 |
| 溶解度 | Ethanol: 10 mg/ml,PBS (pH 7.2): 10 mg/ml/12 mg/mL in DMSO | 储存条件 | Store at -20°C,stored under nitrogen |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 6.2035 mL | 31.0174 mL | 62.0347 mL |
| 5 mM | 1.2407 mL | 6.2035 mL | 12.4069 mL |
| 10 mM | 0.6203 mL | 3.1017 mL | 6.2035 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。